The Low Post News

Eli Lilly Reaches Licensing Deal for Cialis with Sanofi

If two of the rather large drug makers in the world get their way, Cialis the impotence medication may be purchased directly off the shelves of pharmacies in just a few years, without a prescription from a doctor.

Eli Lilly, the maker of Cialis has entered into a licensing deal that allows Sanofi SA the French drug maker to sell a version of Cialis that is nonprescription in major markets when or if regulators approve it.

The erectile dysfunction medication that requires a prescription took in over $2.2 billion in sales around the globe during 2013, surpassing Viagra, its rival, which had $1.9 billion in sales.

The two companies say that the over the counter version of Cialis could provide better and easier access to treatment for those who suffer impotence and could help stop the illicit sales online of stolen or fake Cialis.

The few options available over the counter currently found at pharmacies included dietary supplements that are not approved by the U.S. Food and Drug Administration that claim they enhance the potency of men, such as Libido Max and ExtenZe.

Sanofi will acquire the exclusive rights of seeking approval from regulators for the Cialis over the counter version in Australia, Canada, Europe and the U.S. Sanofi will start selling it, after certain patents have expired for tadalafil, the generic name for Cialis.

Patents will not expire prior to 2017 in Europe and the U.S.

However, the project of over the counter will face many hurdles including its safety concerns.

Sanofi will need to demonstrate to drug regulators that men are able to correctly decide if they need to take the medication and use it with care, without the guidance of a doctor.

Cialis, just like Viagra, could cause the user’s blood pressure to suddenly drop if taken at the same time with certain blood pressure and heart medication, causing the user to faint of die.

Pfizer Inc applied for approval from European regulatory authorities to switch Viagra to over the country status as long as 7 years ago, but then withdrew its application a year later when and advisory board with the regulator expressed concerns this type of product would be misused.

Leave a Reply

Your email address will not be published. Required fields are marked *